IMMUTEP LTD/S ADR (NASDAQ:IMMP) price target set to $7.00 by Maxim Group

ME Staff
-
0

Analyst Ratings For IMMUTEP LTD/S ADR (NASDAQ:IMMP)

Today, Maxim Group set its price target on IMMUTEP LTD/S ADR (NASDAQ:IMMP) to $7.00 per share.

There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on IMMUTEP LTD/S ADR (NASDAQ:IMMP) is Buy with a consensus target price of $7.3750 per share, a potential 188.09% upside.

Some recent analyst ratings include

  • 9/28/2018-IMMUTEP LTD/S ADR (NASDAQ:IMMP) has coverage initiated with a Buy ➝ Buy rating and $7.75 price target
  • 4/19/2017-IMMUTEP LTD/S ADR (NASDAQ:IMMP) had its Buy rating reiterated by FBR & Co


    About IMMUTEP LTD/S ADR (NASDAQ:IMMP)
    Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.

    Recent Trading Activity for IMMUTEP LTD/S ADR (NASDAQ:IMMP)
    Shares of IMMUTEP LTD/S ADR closed the previous trading session at 2,56 −0,10 3,76 % with 2.61 shares trading hands.